[Multidisciplinary therapy for recurrent pancreatic cancer]

Area of Science:

• Oncology
• Radiotherapy

Background:

• Pancreatic cancer frequently metastasizes to distant organs, posing significant treatment challenges.
• Surgical resection followed by adjuvant therapy is a standard approach for resectable pancreatic cancer.

Observation:

• Two Stage III pancreatic cancer patients underwent pancreaticoduodenectomy (PD).
• Case 1: Lung metastases were detected 48 months post-PD and treated with SBRT, with the patient surviving 23 months post-SBRT.
• Case 2: Liver metastases were detected 12 months post-PD and treated with SBRT, but the patient succumbed to lymph node metastasis 32 months post-SBRT.

Findings:

• SBRT can be a treatment option for distant pancreatic cancer metastases in the lung and liver.
• Treatment outcomes for distant metastases vary, influenced by factors such as metastatic site and disease burden.

Implications:

• These cases highlight the potential role of SBRT in managing oligometastatic pancreatic cancer.
• Further research is warranted to optimize SBRT protocols and patient selection for metastatic pancreatic cancer.